ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 323.2% in March

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 187,900 shares, an increase of 323.2% from the February 28th total of 44,400 shares. Approximately 7.5% of the shares of the company are sold short. Based on an average trading volume of 830,400 shares, the short-interest ratio is presently 0.2 days.

ZyVersa Therapeutics Stock Down 13.1 %

Shares of ZyVersa Therapeutics stock opened at $0.61 on Friday. The firm’s fifty day simple moving average is $1.10 and its 200-day simple moving average is $1.46. ZyVersa Therapeutics has a 12 month low of $0.60 and a 12 month high of $8.05.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC purchased a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 1.08% of ZyVersa Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 3.91% of the company’s stock.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.